Jazz Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +11.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 8.9% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 68.1x | Better than 6% |
| Forward P/E | 11.7x | Better than 69% |
| Price / Sales | 3.1x | Better than 40% |
| P/E vs own 5-yr range | 88th pctl | Better than 17% |
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 5.3% | Better than 48% |
| Net income CAGR (3Y) | 20.2% | Better than 73% |
| Free cash flow CAGR (3Y) | 14.0% | Better than 58% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 88.2% | Better than 96% |
| Operating margin | 12.1% | Better than 57% |
| Net margin | -8.3% | Better than 17% |
| Return on equity | -8.5% | Better than 21% |
| Return on invested capital | -2.1% | Better than 25% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -9.4% | Better than 52% |
| 6-month return | -4.0% | Better than 48% |
| 12-month return (ex latest month) | 21.3% | Better than 60% |
| Distance below 52-week high | 13.6% | Better than 75% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 52% |
| Debt to assets | 46.5% | Better than 19% |
| Interest coverage | -2.2x | Better than 20% |
| Free cash flow / net income | 240.6% | Better than 82% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 33.4% | Better than 53% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 236.45
- Open
- 235.19
- Day range
- 227.95 - 238.59
- Avg price
- 230.97
- Volume
- 984.70K
- Turnover
- 227.43M
- Turnover ratei
- 1.58%
- Volume ratioi
- 1.35
- Amplitudei
- 4.50%
- 52-week rangei
- 156.95 - 266.38
Valuation
- P/Ei
- -39.43
- P/E (TTM)i
- 68.12
- P/Bi
- 3.53
- EPSi
- -5.84
- Book value / shi
- 65.30
- Net profit
- -374.86M
- Net assets
- 4.19B
Share structure
- Market cap
- 14.78B
- Float capi
- 14.33B
- Shares out
- 64.19M
- Float sharesi
- 62.25M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
13.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.19M net over the window
Short interest
- Shares short
- 5.80M
- % of floati
- 8.93%
- Days to coveri
- 7.67
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
Jazz Pharmaceuticals last traded at 230.26. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Jazz Pharmaceuticals's market cap?
About 14.78B.
What is the P/E ratio of Jazz Pharmaceuticals?
The trailing twelve-month P/E is 68.12, above its own 5-year average of 59.96 — toward the top of its historical range (89.08% percentile). See the Valuation tab for the full history.
Does Jazz Pharmaceuticals pay a dividend?
Jazz Pharmaceuticals does not currently pay a regular dividend.
Is Jazz Pharmaceuticals a buy according to analysts?
The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 306.38, which implies 33.1% upside from the current price. This is not investment advice.
What is Jazz Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Jazz Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.
Jazz Pharmaceuticals discussion 0 comments